A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell Transplantation

Diagnosis and Management of Multiple Myeloma

(2022) Andrew J. Cowan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

(2022) Hartmut Goldschmidt et al.   Lancet Haematology

Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial

(2021) Lisa B. Leypoldt et al.   LEUKEMIA

Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN

(2020) Peter M Voorhees et al.   BLOOD

Newly diagnosed multiple myeloma: current treatment strategies, emerging therapeutic approaches and beyond

(2020) Mehmet H Kocoglu et al.   Expert Review of Hematology

Multiple myeloma current treatment algorithms

(2020) S. Vincent Rajkumar et al.   Blood Cancer Journal

Current status of autologous stem cell transplantation for multiple myeloma

(2019) Rama Al Hamed et al.   Blood Cancer Journal

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

(2019) Philippe Moreau et al.   LANCET

Efficacy and safety of plerixafor for hematopoietic stem cell mobilization for autologous transplantation in patients with non‑Hodgkin lymphoma and multiple myeloma: A systematic review and meta‑analysis

(2019) Xiaoyang Yang et al.   Experimental and Therapeutic Medicine

Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma

(2019) Abdullah S. Al Saleh et al.   AMERICAN JOURNAL OF HEMATOLOGY

Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score

(2018) Jacopo Olivieri et al.   BONE MARROW TRANSPLANTATION

Autograft immune effector cells and survival in autologous peripheral blood hematopoietic stem cell transplantation

(2017) Luis F. Porrata   JOURNAL OF CLINICAL APHERESIS

How to manage poor mobilizers for high dose chemotherapy and autologous stem cell transplantation?

(2017) Pinar Ataca Atilla et al.   TRANSFUSION AND APHERESIS SCIENCE

Plerixafor for stem cell mobilization

(2016) Yavuz M. Bilgin et al.   CURRENT OPINION IN HEMATOLOGY

Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure

(2016) Nina Worel et al.   JOURNAL OF CLINICAL APHERESIS

Frontline therapy of multiple myeloma

(2015) P. Moreau et al.   BLOOD

Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective

(2015) F Saraceni et al.   BONE MARROW TRANSPLANTATION

Peripheral Blood Progenitor Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation

(2014) Hien K. Duong et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation

(2014) M Mohty et al.   BONE MARROW TRANSPLANTATION

Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma

(2014) Michael Hundemer et al.   JOURNAL OF CLINICAL APHERESIS

Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations

(2013) Sergio Giralt et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Plerixafor Plus Granulocyte Colony-Stimulating Factor versus Placebo Plus Granulocyte Colony-Stimulating Factor for Mobilization of CD34+ Hematopoietic Stem Cells in Patients with Multiple Myeloma and Low Peripheral Blood CD34+ Cell Count: Results of a Subset Analysis of a Randomized Trial

(2012) Auayporn P. Nademanee et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Lenalidomide-induced upregulation of CXCR4 in CD34+ hematopoietic cells, a potential mechanism of decreased hematopoietic progenitor mobilization

(2012) S Li et al.   LEUKEMIA

Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program

(2010) K Hübel et al.   BONE MARROW TRANSPLANTATION

review: Current status of stem cell mobilization

(2010) Morie A. Gertz   BRITISH JOURNAL OF HAEMATOLOGY

Impairment of Filgrastim-Induced Stem Cell Mobilization after Prior Lenalidomide in Patients with Multiple Myeloma

(2009) Uday Popat et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Poor Mobilization of Hematopoietic Stem Cells—Definitions, Incidence, Risk Factors, and Impact on Outcome of Autologous Transplantation

(2009) Patrick Wuchter et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

(2009) J. F. DiPersio et al.   BLOOD

Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous Transplantation

(2008) Iskra Pusic et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma

(2008) H Paripati et al.   LEUKEMIA